Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated recombinant human megakaryocyte growth and development factor
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is a truncated, nonglycosylated form of the amino-terminal 163 amino acids of human thrombopoietin (TPO), covalently linked to a 20-kDa polyethylene glycol moiety. It acts as an Mpl-ligand that stimulates the proliferation and differentiation of megakaryocytes in bone marrow, leading to increased platelet production. The drug was developed for the management of severe thrombocytopenia, particularly in patients undergoing chemotherapy or with advanced cancer. Pegylation extends its plasma half-life to approximately 25–35 hours compared to non-pegylated forms. Clinical studies demonstrated dose-dependent increases in platelet counts with low toxicity; platelets produced were morphologically and functionally normal[1][2][3][5][6].
- Other names
- pegylated recombinant human megakaryocyte growth and development factorPEG-rHuMGDFpegylated human megakaryocyte growth and development factor
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on pegylated recombinant human megakaryocyte growth and development factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated recombinant human megakaryocyte growth and development factor.